



**HA NOI CPC1 PHARMACEUTICAL
JOINT STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

No. *66* /2026/CV-CPC1HN

Ha Noi, March 28, 2026

Ref: Explanation regarding the profit after tax on the
2025 Income Statement changing by 10% or more
compared to the 2024

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Pursuant to the Ministry of Finance's Circular 96/2020/TT-BTC, dated 16 November 2020, of guidance on information disclosure on the stock market.

Based on the Income Statements in the 2025 and 2024 Financial Statements, Hanoi CPC1 Pharmaceutical Joint Stock Company hereby provides the following explanation for the 2025 Financial Statements:

- + Profit after tax in 2025: VND 283.441 billion
- + Profit after tax in 2024: VND 237.232 billion

Profit after tax in 2025 increased by VND 46.209 billion compared to 2024, representing a growth of more than 10% over the same period.

• **Main reasons for this decrease:**

- Net revenue from sales of goods and provision of services in 2025 increased by 31,06 %, equivalent to an increase of VND 401.646 billion compared to the same period in 2024. In 2025, the Company strengthened sales through distribution channels, resulting in higher sales revenue.
- In addition, in 2025, the Company flexibly managed and effectively controlled cash flows. Combined with a decrease in market interest rates, this led to a 33,51% reduction in financial expenses compared to the same period last year.
- The increase in revenue corresponded to an increase in profit; therefore, Profit after tax in 2025 rose by VND 46.209 billion compared to 2024..

The above is the explanation of Hanoi CPC1 Pharmaceutical Joint Stock Company regarding the change of 10% or more in profit after tax in the 2025 Income Statement compared to 2024.

Sincerely,

Recipients:

- As addressed;
- Filing: Office Copy

CHAIRMAN OF THE BOARD OF DIRECTORS



Le Nam Thang